For this expansion, Galapagos receives a payment of E2 million cash from GlaxoSmithKline (GSK). This payment is in addition to the existing alliance terms, making the total alliance now worth up to E188 million.
Including the latest payment, Galapagos has received a total of E17.9 million in payments from GSK under this alliance.